CAMBRIDGE, Mass. — The Food and Drug Administration has approved a new drug for multiple sclerosis.
Sanofi subsidiary Genzyme announced that the FDA had approved Aubagio (teriflunomide) as a once-daily, oral treatment for patients with relapsing MS.
"We are very excited to introduced Aubagio as a new treatment option that can make a difference in the lives of people with multiple sclerosis," Genzyme president and CEO David Meeker said. "The approval of our first MS therapy represents an important milestone for Genzyme and underscores our commitment to long-term leadership and partnership in the MS community."